BiotechTube
Borea Therapeutics

Borea Therapeutics

Milan, Italy· Est.
boreatherapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3M

Overview

Borea Therapeutics is a private, preclinical-stage biotech developing next-generation viral vectors for targeted gene therapy. The company is building a proprietary platform aimed at overcoming key limitations in gene delivery to create treatments for a range of genetic and chronic conditions. Based in Milan, Italy, and founded in 2020, the firm is currently in the research and platform development phase, positioning itself in the rapidly advancing field of advanced therapeutics. Its success will depend on the technical validation of its vector technology and its ability to advance programs into clinical development.

Genetic DiseasesChronic Diseases

Technology Platform

Proprietary platform for developing next-generation, targeted viral vectors for gene therapy, aiming for a universal and safe gene transfer system.

Funding History

1
Total raised:$3M
Seed$3M

Opportunities

The global gene therapy market offers massive growth potential, driven by high unmet need.
There is a significant opportunity for improved viral vector technology that enhances safety, targeting, and manufacturability compared to current standards.
Success could lead to valuable partnerships or acquisition by larger pharmaceutical companies.

Risk Factors

The company faces high technical risk that its novel vector platform may not perform as intended in preclinical models.
As a pre-revenue startup, it is dependent on external financing in a competitive funding landscape.
It also operates in a highly competitive field with well-resourced players pursuing similar vector engineering goals.

Competitive Landscape

Borea competes in the crowded and fast-moving field of viral vector and gene therapy platform development. Competitors range from large-cap biotechs with approved therapies (e.g., Spark, BioMarin) to numerous private platform companies (e.g., Dyno Therapeutics, Affinia) leveraging AI and protein engineering. Differentiation will require demonstrating clear functional advantages.

More companies in Cell & Gene Therapy →More companies in Italy →